SPEAKER BIOGRAPHIES: Antibodies for the 21st Century
David Meininger, Ph.D., Executive Director, Molecular Discovery, Merck
Dr. Meininger joined Merck in 2011 as Head of Protein Sciences. He serves as a member of the Biologics RLC, is co-champion of the Ambrx antibody-drug conjugate collaboration and plays a strategic role on multiple Merck partnerships. Dr. Meininger is responsible for oversight of lead generation efforts in support of biotherapeutic programs spanning indications throughout Merck's Disease Area Franchises. Prior to joining Merck, Dr. Meininger held positions with Amgen, Boehringer Ingelheim, Genentech, and Tularik. Dr. Meininger holds a Ph.D. in Chemistry from the University of California, San Diego, a M.B.A. in Technology Management from the University of Washington and a B.S. in Chemistry from the University of Florida.
Randal R. Ketchem, Ph.D., Scientific Director, Therapeutic Discovery, Amgen, Inc.
Randal R. Ketchem received his Ph.D. in Molecular Biophysics from the Florida State University, followed by postdoctoral research at The Scripps Research Institute, focusing in both on protein structure and computational biology. Now a scientific director at Amgen, he leads the Protein and Antibody Optimization group within Therapeutic Discovery.
Vaughn Smider, M.D., Ph.D., Assistant Professor, Molecular Biology, The Scripps Research Institute
Dr. Smider received his MD and PhD in Immunology from Stanford University. He is the founder of Fabrus, Inc., and is also currently an Assistant Professor of Molecular Biology at The Scripps Research Institute in La Jolla, California.
Madan Katragadda, Ph.D., Senior Principal Scientist, Global Biotherapeutic Technologies, Pfizer, Inc.
Madan Katragadda is a senior principal scientist in the Biotherapeutics discovery and engineering group at Pfizer and has experience in the discovery of various biotherapeutic modalities that include peptides, Fc fusions, monoclonal antibodies, antibody-drug conjugates and bispecifics.
Yvette Stallwood, Ph.D., Head, Applied Protein Services, Lonza Biologics
Yvette studied Microbiology and Virology at Warwick University, UK and then completed a PhD in Oncology at the University of Birmingham, UK, where she studied the use of Viral Directed Gene Therapy for the treatment of Ovarian Cancer. Previous roles have involved the research and development of immunomodulatory therapies and treatments for Parkinsons Disease and other amyloid diseases. Yvette has been with Lonza for five years and is currently Head of the Applied Protein Services Department in Cambridge, UK, which offer a mix of in silico and in vitro activities to support late stage discovery and early stage development of vaccines and biotherapeutics, including the prediction and assessment of Immunogenicity, reduction of Aggregation, Protein Engineering and production of recombinant proteins using mammalian and microbial expression platforms.
Steffen Goletz, Ph.D., CEO and Founder, Glycotope GmbH
Dr. Steffen Goletz, CEO, CSO and co-founder of the biotech company GLYCOTOPE, studied biology, biochemistry and molecular biology at the universities in Heidelberg, Kaiserslautern, Manchester (UK) and Berlin and holds a Ph.D. in biochemistry. During his scientific career he worked for renowned research institutions including the Max Delbrueck Centre for Molecular Medicine (Berlin), the MRC Centre for Protein Engineering (Cambridge, UK), and the German Cancer Research Centre in Heidelberg. During his research, Dr. Goletz has focused on glycobiology, tumor immunology, antibody engineering and cellular engineering. As CSO, Steffen is responsible for the extremely successful development of GLYCOTOPEs product pipeline of glycooptimized biotherapeutics with four products currently in clinical trials. GLYCOTOPE developed the novel expression platform GlycoExpress based on human glycoengineered cell lines which is used for the generation of improved biopharmaceuticals with fully human and optimized glycosylation.
Sergej Kiprijanov, Ph.D., Vice President, Discovery, Research and Pre-clinical Development, Affitech AS
Dr. Sergej Kiprijanov, Ph.D., carried out his postdoctoral research at the German Cancer Research Center (DKFZ) in Heidelberg (Germany), where he played a key role in design and generation of the novel bispecific antibody formats useful for tumor therapy. In 2000-2006, he has been a Head of Antibody Engineering and then a Head of Research and Development at Affimed Therapeutics in Heidelberg (Germany) focusing on engineering bispecific antibodies for cancer indications. In particular, he is an inventor of the bispecific TandAb technology (main asset of Affimed Therapeutics); co-inventor of a fully human highly specific antibody against A isoform of human FcγRIII (CD16) expressed on NK cells; inventor and developer of AFM13 (bs CD30 × CD16a TandAb) which is currently in clinical trials for treatment of Hodgkin's lymphoma. Afterwards, Dr. Kiprijanov has served as a Chief Scientific Officer at Novoplant (Gatersleben, Germany), a German plant biotech company expressing antibodies in seeds of transgenic plants for treatment of infectious diseases in production animals. In 2008, he joined Affitech (Oslo, Norway) as Vice President of Discovery, Research and Preclinical Development, dealing with generation of fully human therapeutic antibodies mainly against challenging targets, such as membrane-bound G-protein coupled receptors (GPCR). Dr. Kiprijanov has authored more than 70 research articles, reviews and book chapters and is named as an inventor on 30 patents and patent applications.
Cory Bentley, Ph.D., Senior Scientist, Fabrus LLC
Dr. Bentley received her PhD in Biomedical Sciences from the University of California, San Diego. After completing postdoctoral work at Brown University and the Genomics Institute of the Novartis Research Foundation (GNF), she joined Fabrus, Inc. Fabrus is a biotech startup in San Diego with a novel antibody platform focused on developing functional therapeutic antibodies.
Harald Kolmar, Ph.D., Professor and Head, Biochemistry, Technical University Darmstadt
Harald Kolmar is full professor at the Technische Universität Darmstadt, Germany where since 2005 he heads the Department of Applied Biochemistry. He holds a Ph.D. and habilitation in biochemistry and molecular genetics from university of Tübingen and Göttingen. His current scientific interests mainly focus on protein engineering and design, nanobiotechnology, antibody engineering, chemical biology and development of tailor-made peptides and miniproteins for applications in diagnostics and therapy.
Christoph Freiberg, Ph.D., Senior Scientist, Cell and Protein Sciences, Bayer HealthCare
Christoph Freiberg, Ph.D. is a biologist working since 2007 as senior scientist and project manager in Bayer HealthCare’s Biologics Researchin Wuppertal, Germany. He is heading a laboratory responsible for protein expression and cell line development and is leading biologics data management as well as lead optimization projects.
Before, Christoph worked as Professor for Applied Biochemistry and Bioinformatics in the Department of Chemistry at the Niederrhein University of Applied Sciences in Krefeld (Germany) and as research scientist and project manager in Bayer’s Antiinfectives Research and non-clinical development.
Christoph was educated at the Universities of Göttingen, Marburg and Jena, Germany (Diploma in Biology, Ph.D. in Molecular Biology).
Andreas Menrad, Ph.D., Chief Scientific Officer, Ablynx
Andreas Menrad joined Ablynx from Genzyme where he served as General Manager and Vice President Antibody Therapeutics. Prior to his position at Genzyme, Andreas held science and management positions in preclinical research dermatology and oncology at Schering AG, Berlin, Germany. During his career in pharmaceutical industry, Andreas progressed both NCE and NBE from bench to bedside. He received his PhD from the University of Stuttgart and held a research position as a post doctoral fellow at the Wistar Institute in Philadelphia, USA.
Stefan Seeber, Ph.D., Principal Scientist, Molecule and Cell Line Development, Roche Diagnostics GmbH
Stefan Seeber is a Principal Research Scientist in the Cell Line and Molecule Development department at Roche. Dr. Seeber received his Diploma in Biology from the Technical University Munich and his Ph.D. from the University of Tübingen, Germany. In 1990 he joined the Biologics Research group of Boehringer Mannheim GmbH in Penzberg and continued his work at Roche in Penzberg. Since then he has been involved in the pre-clinical development of numerous therapeutic antibodies with a focus on lead identification, optimization and cell line development. His special interest is in the optimization and automation of lead identification processes.